NantKwest Inc. (NK)
Symbol Info
Listed Symbol NK
Name NantKwest Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $47,000
Latest Fiscal EPS $-1.22
Price Info
21 Day Moving Average $1.2705
21 Day EMA $1.257740
50 Day Moving Average $1.1686
50 Day EMA $1.212450
200 Day EMA $1.585620
200 Day Moving Average 1.352800
52 Week High $4.23
52 Week Low $0.93
52 Week Change $-60.063900
Alpha -0.052439
Beta 2.3059
Standard Deviation 0.249056
R2 0.115246
Periods 49
Share Information
10 Day Average Volume 127,172
20 Day Average Volume 199,148
30 Day Average Volume 207,944
50 Day Average Volume 307,286
Outstanding Shares 98,307,859
Float Shares 93,789,465
Percent Float 95.40%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 133
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 554,893
Institute Holdings Percent 10.200000
Institute Sold Previous 3 Months 2,993,599
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 4.60%
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,518,394
Price Change
7 Day Price Change $-0.11
7 Day Percent Change -8.09%
21 Day Price Change $-0.01
21 Day Percent Change -0.79%
30 Day Price Change $-0.04
30 Day Percent Change -3.10%
Month To Date Price Change $-0.13
Month To Date Percent -9.42%
90 Day Price Change $0.140000
90 Day Percent Change 12.61%
Quarter To Date $0.230000
Quarter To Date Percent 22.55%
180 Day Price Change $0.120000
180 Day Percent Change 10.62%
200 Day Price Change $0.160000
200 Day Percent Change 14.68%
Year To Date $0.090000
Year To Date Percent 7.76%
Profile
Description NantKwest Inc is a United States-based firm functioning in the healthcare sector. It is focused on providing immunotherapeutic agents, especially natural killer cells to treat cancer, infectious and inflammatory diseases. Natural Killer (NK) cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. The company's drug candidates such as activated NK cells, high-affinity NKs and target activated NK's address virally-induced cancers, viral, fungal and bacterial infections as well as critical diseases such as Ebola. Its pipeline product includes taNK, haNK, and aNK. Most of NatWest's sales are concentrated in the United States region although it has a reasonable market in Europe and other Non-U.S. territories.
Details
Issue Type CS
Market Cap $122,884,824
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 98,307,859
CEO Patrick Soon-Shiong
Employees 151
Last Audit UQ
Classification
CIK 0001326110
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 3530 John Hopkins Court
San Diego, CA 92121
Website http://www.nantkwest.com
Facisimile
Telephone +1 858 633-0300
Email investors@nantkwest.com
Key Ratios
Profitability
EBIT Margin -125,891.7
EBITDA Margin -108,951.7
Pre-Tax Profit Margin -159,701.8
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $60,000
Revenue Per Share $0.0006
Revenue 3 Years $7.30
Revenue 5 Years $-40.04
Valuation Measures
PE Ratio -
Enterprise Value $52,846,745
Price To Sales 2,048.080300
Price To Free Cash -1.7
PE High Last 5 Years -
Price To Book 0.8
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.8
Financial Strength
Total Debt To Equity 0.1
Int Coverage -254.3
Current Ratio 7.0
Leverage Ratio 1.2
Quick Ratio 6.8
Long Term Debt To Capital 0.07
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -39.03
Return On Equity -45.38
Return On Capital -42.51
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
NK
NantKwest
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.